Showing results (391-400 of 1,983) with videos related to

Sort By:
Pageof 199
The Lancet. Neurology|October 15, 2017
The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causesAstrid J Terkelsen, Páll Karlsson, Giuseppe Lauria, et al.
The Lancet. Neurology|November 11, 2017
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialIvo N van Schaik, Vera Bril, Nan van Geloven, et al.
The Lancet. Neurology|September 19, 2017
Therapies targeting DNA and RNA in Huntington's diseaseEdward J Wild, Sarah J Tabrizi
The Lancet. Neurology|September 22, 2017
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
The Lancet. Neurology|November 25, 2015
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort studyClifford R Jack, Terry M Therneau, Heather J Wiste, et al.
The Lancet. Neurology|June 13, 2016
Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysisWilliam N Whiteley, Jonathan Emberson, Kennedy R Lees, et al.
The Lancet. Neurology|June 16, 2016
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trialThorsten Steiner, Sven Poli, Martin Griebe, et al.
The Lancet. Neurology|June 16, 2016
Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN)Albert J Yoo, Olvert A Berkhemer, Puck S S Fransen, et al.
The Lancet. Neurology|June 14, 2016
Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Valery L Feigin, Gregory A Roth, Mohsen Naghavi, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialJeffrey A Cohen, Douglas L Arnold, Giancarlo Comi, et al.
Pageof 199